![Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1476558616301804-gr5.jpg)
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
![Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer | Clearity Foundation Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer | Clearity Foundation](https://www.clearityfoundation.org/wp-content/uploads/2021/12/mirvetuximab-scaled.jpeg)
Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer | Clearity Foundation
![Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1a2eefe5-9006-41f8-ac48-95d1644d314e/gr3_lrg.jpg)
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
![ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer | Business Wire ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer | Business Wire](https://mms.businesswire.com/media/20191217005102/en/763320/22/immunogen-logo.jpg)
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer | Business Wire
![Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-021-00868-x/MediaObjects/41392_2021_868_Fig1_HTML.png)
Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy
![Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer - Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/43fba8e9-51bb-42e7-b2cf-ee8ab3e680cd/gr1.jpg)
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer -
![Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study | Journal of Clinical Oncology Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2017/jco.2017.35.issue-10/jco.2016.69.9538/20171010/images/large/jco.2016.69.9538t2.jpeg)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study | Journal of Clinical Oncology
![Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1476558616301804-gr1.jpg)
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
![PDF) Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models PDF) Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models](https://www.researchgate.net/publication/310838632/figure/fig4/AS:668528747225092@1536401082502/In-vivo-antitumor-activity-of-IMGN853-in-combination-with-bevacizumab-A-Mice-bearing_Q320.jpg)
PDF) Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
![Targeting the folate receptor for the treatment of ovarian cancer - Lutz - Translational Cancer Research Targeting the folate receptor for the treatment of ovarian cancer - Lutz - Translational Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/3/articles/3838/public/3838-PB4-R1.png/w300)
Targeting the folate receptor for the treatment of ovarian cancer - Lutz - Translational Cancer Research
![Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. - Abstract - Europe PMC Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5126132/bin/gr3.jpg)
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. - Abstract - Europe PMC
![Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13550-018-0437-x/MediaObjects/13550_2018_437_Fig1_HTML.png)
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
![Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13550-018-0437-x/MediaObjects/13550_2018_437_Fig5_HTML.png)
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
![Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors - Moore - 2017 - Cancer - Wiley Online Library Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors - Moore - 2017 - Cancer - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/5be668f8-037b-4798-be52-619d9a28f39f/cncr30736-fig-0001-m.jpg)
Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors - Moore - 2017 - Cancer - Wiley Online Library
![Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-11-00032/article_deploy/html/images/pharmaceuticals-11-00032-g001-550.jpg)
Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML
![Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e045098a-d6c6-4f15-8576-0e763c167144/gr2_lrg.jpg)
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
![Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-022-00947-7/MediaObjects/41392_2022_947_Fig1_HTML.png)
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
![FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer | Future Oncology FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2017-0646/asset/images/medium/figure1.gif)